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Cervical cancer caused by the Human Papilloma Virus is the most common among 
gynaecological cancers (Burd, 2003). Cisplatin is usually the primary drug choice in 
chemotherapeutic treatment of this cancer type, either in a monotherapy or in combination 
with other antineoplastic agents. However, there are several setbacks in the application of 
anticancer drugs including poor absorption, poor bioavailability, and side effects such as 
nausea, alopecia etc. 
Biodegradable silica-gelatin hybrid aerogels have been developed as promising drug delivery 
systems and showed significant cytotoxicity towards cancer cells when loaded with 
anticancer agents (Nagy et al., 2019). 
Our objective is to develop a biodegradable, mucoadhesive drug carrier vehicle using the sol-
gel method, functionalization with cisplatin and supercritical drying. The resulting aerogels 
are mesoporous and contain Cisplatin in coordination bonds. The drug is predicted to be 
released on a pH responsive profile. We aim to investigate the biocompatibility, 
bioavailability, and cytotoxicity of this DDS on HeLa and Caco-2 cells using the MTT Assay 
and the Real Time Cell Analyser techniques. Based on the in vitro results, the study furthers 
on to the formulation of ovulum, suppositories, vaginal creams, vaginal tablets, and other 
vaginal preparations for the local delivery of cisplatin in the cervical tumour tissue 
environment, for in vivo studies. 
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